SOTIO Wins 2016 Global Innovation & Excellence Award for "Innovation in New Medicine Production"

April 5, 2016
Source: Press Release, Prague/Boston

SOTIO, a biotechnology company owned by PPF Group, announced today that it has been named as one of the winners of the Global Corporate LiveWire Innovation & Excellence Awards. SOTIO was presented with two awards: a global award for “Innovation in New Medicine Production” and a Czech-specific award for “Innovation & Excellence in Biotechnology”.

Ladislav Bartoníček, CEO of SOTIO, said: "We are very proud to have won these awards. It shows that with effort and dedication the company based in the CEE region can diversify and have a chance of succeeding in a tough global competition. These prestigious awards prove that we have established a really strong international team focused on effective research, manufacturing, clinical development and business development.”

The Corporate LiveWire Innovation & Excellence Awards give recognition to businesses that are transforming their respective industries. The award winners redefine standards of excellence by continually setting industry trends and lead the way in innovation and improvement. The full winners guide can be found at: http://www.corporatelivewire.com/awards.html?award=88. (for SOTIO awards see pages 21 & 82, password is ‚innovationawards2016‘). Corporate LiveWire provides business professionals and individuals in the corporate sector with information on the latest news and developments from around the globe. The resource offers regular up to date content on an array of subject areas such as corporate transactions, international markets, business strategy and changes in legislation.

SOTIO is developing new medical therapies, focusing on the treatment of cancer and autoimmune diseases. The company’s current focus is predominantly on development of its Active Cellular Immunotherapy (ACI) treatment for prostate cancer patients (DCVAC/PCa), patients with ovarian cancer (DCVAC/OvCa), and patients with lung cancer (DCVAC/LuCa). In addition, SOTIO’s in-house research and clinical development teams are investigating potential uses of the ACI treatment on patients with other health issues.

SOTIO is also leading the PPF Group’s effort to build a diverse biotechnology portfolio through collaborations, in-licensing, investments, mergers and acquisitions. SOTIO is looking to partner with other companies and institutions that develop promising biotechnology projects.

We use cookies to give you the best possible experience on our website. More information